Immunome, Inc.IMNMNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 93,000 shares of common stock to three new employees under the Company's 2024 Indu.

businesswire.com

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will b.

defenseworld.net

Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall purchased 4,729 shares of the firm's stock in a transaction on Tuesday, December 30th. The shares were purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the completion of the transaction, the chief executive officer owned 665,254 shares

defenseworld.net

Isaac Barchas Sells 383,200 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) Director Isaac Barchas sold 383,200 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued

defenseworld.net

Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall acquired 7,278 shares of the company's stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $20.48 per share, with a total value of $149,053.44. Following the purchase, the chief executive officer owned 860,525 shares of the company's

seekingalpha.com

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026.

businesswire.com

Immunome Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offe.

defenseworld.net

Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase of approximately 347% compared to the typical volume of 650 call options. Wall Street Analysts Forecast Growth A number of analysts recently commented on the

fool.com

Why Immunome Stock Surged Today

A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.

businesswire.com

Immunome Announces Proposed Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day.

investors.com

Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA

Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug.

reuters.com

Immunome's experimental drug meets main goal in late-stage study

Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.

businesswire.com

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. The trial met its primary endpoint of improving progression-free survival, demonstrating a statistically si.

businesswire.com

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Pres.

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company's 2024 Indu.

defenseworld.net

Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM

Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ: IMNM) by 17.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,565 shares of the company's stock after purchasing an additional 6,141 shares during the period. Intech Investment Management LLC's holdings in

businesswire.com

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference Presentation Date/Time: December 3, 2025, at 9 a.m. ET 8th Annual Evercore Healthcare Conference Presentation Date/Time: December 3, 2025, at 9:10 a.m. ET Interested parti.

businesswire.com

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and provided a business update. “Immunome's pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end.

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 19,000 shares of common stock to three new employees under the Company's 2024 Induceme.

defenseworld.net

Brighton Jones LLC Invests $98,000 in Immunome, Inc. $IMNM

Brighton Jones LLC acquired a new position in Immunome, Inc. (NASDAQ: IMNM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,491 shares of the company's stock, valued at approximately $98,000. Other institutional investors and hedge funds

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance